Serum Zn content in tumor-bearing rats treated with anticancer drugs.
- 1 January 1979
- journal article
- research article
- Published by Tohoku University Medical Press in The Tohoku Journal of Experimental Medicine
- Vol. 129 (2) , 111-121
- https://doi.org/10.1620/tjem.129.111
Abstract
The serum Zn content in rats bearing Yoshida-Sarcoma, [ascites hepatomas] AH 66F, AH 13 or AH 109A was low as compared with that in normal controls. In the rats which had received i.p. inoculum of Yoshida-Sarcoma, the effects of anticancer drugs were closely related to the changes in serum Zn content. Serum Zn content increased and approached the normal range almost in parallel with the prolongation of survival time by anticancer drugs. As the causes responsible for the reduction in quantity of serum Zn in the tumor-bearing rats, the reduction of serum albumin content and the accumulation of Zn in the tumor tissue and organs such as the liver and kidneys were suggested.This publication has 3 references indexed in Scilit:
- A Zn++ Requirement for Synthesis of Deoxyribonucleic Acid by Rat LiverJournal of Biological Chemistry, 1964
- ZINC METABOLISM IN PATIENTS WITH SYNDROME OF IRON DEFICIENCY ANEMIA HEPATOSPLENOMEGALY DWARFISM AND HYPOGONADISM1963
- Studies on zinc in blood. Transport of zinc and incorporation of zinc in leucocytesBiochemical Journal, 1962